Portage Biotech Inc. reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported net loss was USD 39.37 million compared to USD 7.49 million a year ago. Basic loss per share from continuing operations was USD 1.88 compared to USD 0.44 a year ago. Diluted loss per share from continuing operations was USD 1.88 compared to USD 0.44 a year ago.
For the nine months, net loss was USD 50.45 million compared to USD 10.16 million a year ago. Basic loss per share from continuing operations was USD 2.68 compared to USD 0.65 a year ago. Diluted loss per share from continuing operations was USD 2.68 compared to USD 0.65 a year ago.